440 related articles for article (PubMed ID: 23381448)
1. Management of the new patient with CML in chronic phase.
Marin D
Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
[TBL] [Abstract][Full Text] [Related]
2. Drugs offer new hope for patients with CML who are resistant to imatinib.
Oestreicher P
ONS Connect; 2007 Jul; 22(7):20-1. PubMed ID: 17694781
[No Abstract] [Full Text] [Related]
3. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Miura M; Takahashi N
Rinsho Ketsueki; 2013 Oct; 54(10):1720-9. PubMed ID: 24064822
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
Chuah CT; Nakamae H; Shen ZX; Bradley-Garelik MB; Kim DW
Leuk Lymphoma; 2014 Sep; 55(9):2093-100. PubMed ID: 24289108
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
9. Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients.
Breccia M; Alimena G
Curr Cancer Drug Targets; 2012 May; 12(4):391-401. PubMed ID: 22385514
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Jabbour E; Kantarjian H; Cortes J
Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
12. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
[TBL] [Abstract][Full Text] [Related]
13. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.
Harbaum L; Marx A; Goekkurt E; Schafhausen P; Atanackovic D
Int J Hematol; 2014 Jan; 99(1):91-4. PubMed ID: 24264834
[TBL] [Abstract][Full Text] [Related]
14. First-line therapy for chronic myeloid leukemia: Past, present, and future.
Pavlovsky C; Kantarjian H; Cortes JE
Am J Hematol; 2009 May; 84(5):287-93. PubMed ID: 19306355
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
16. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
17. [Adherence and toxicity to tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
González Rosa V; Gutiérrez Nicolás F; Gavira Moreno R; Viña Romero MM; Moreno Carvajal MT; Gázquez Pérez R
Farm Hosp; 2013; 37(6):434-40. PubMed ID: 24256006
[TBL] [Abstract][Full Text] [Related]
18. How I treat newly diagnosed chronic myeloid leukemia in 2015.
Gambacorti-Passerini C; Piazza R
Am J Hematol; 2015 Feb; 90(2):156-61. PubMed ID: 25370814
[TBL] [Abstract][Full Text] [Related]
19. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Breccia M
Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
[No Abstract] [Full Text] [Related]
20. Leukemia. Q&A highlights.
Frame D; Sessions J; Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
